Home > Cardiology > ESC 2022 > Medical therapy as good as PCI for ischaemic cardiomyopathy

Medical therapy as good as PCI for ischaemic cardiomyopathy

Presented By
Prof. Divaka Perera, Guy's & St Thomas' NHS Foundation Trust, London, UK
Conference
ESC 2022
Trial
REVIVED-BCIS2
In patients with severe ischaemic left ventricular systolic dysfunction, percutaneous coronary intervention (PCI) did not reduce the composite incidence of all cause death or hospitalisation for heart failure at a median follow-up of 3.4 years, compared with optimal medical treatment. Furthermore, PCI did not incrementally improve left ventricular ejection fraction (LVEF) or provide a sustained difference in quality-of-life, reported researchers from the first randomised REVIVED-BCIS2 trial in this patient population. Patients with ischaemic cardiomyopathy continue to have high rates of mortality and hospitalisation for heart failure even with contemporary medical and device therapy. Previously, the STICH trial has shown that revascularisation can improve the 10-year outcomes in this vulnerable patient population [1]. The REVIVED-BCIS2 trial (n=700; NCT01920048) s...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on